

Jess M Fernandez-Gmez

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2080979/jesus-m-fernandez-gomez-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42
papers

1,458
citations

16
h-index

38
g-index

75
ext. papers

1,788
ext. citations

2.7
avg, IF

3.5
L-index

#	Paper	IF	Citations
42	Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC). <i>Actas Urológicas Españolas</i> , 2021 , 45, 93-102	0.7	3
41	Efficacy and tolerability of the hexanic extract of <i>Serenoa repens</i> compared to tamsulosin in moderate-severe LUTS-BPH patients. <i>Scientific Reports</i> , 2021 , 11, 19401	4.9	2
40	Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry. <i>Actas Urológicas Españolas</i> , 2020 , 44, 156-163	0.7	
39	Comparative analysis of the expression of metalloproteases (MMP-2, MMP-9, MMP-11 and MMP-13) and the tissue inhibitor of metalloprotease 3 (TIMP-3) between previous negative biopsies and radical prostatectomies. <i>Actas Urológicas Españolas</i> , 2020 , 44, 78-85	0.7	0
38	Clinical Benefit of Tamsulosin and the Hexanic Extract of <i>Serenoa Repens</i> , in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
37	Usefulness of PET/CT 18-FDG for the diagnosis and follow-up of urological, urothelial and kidney tumours. <i>Actas Urológicas Españolas</i> , 2019 , 43, 32-38	0.7	
36	Clinical usefulness of random biopsies in diagnosis and treatment of non-muscle invasive bladder cancer: Systematic review and meta-analysis. <i>Actas Urológicas Españolas</i> , 2018 , 42, 285-298	0.7	5
35	Efficacy and safety of a hexanic extract of <i>Serenoa repens</i> (Permixon) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. <i>BJU International</i> , 2018 , 122, 1049-1065	5.6	39
34	Review of the evidence on handling drugs and hazardous products in Urology Departments. Consensus document between the Spanish Urological Association and the Spanish Society of Hospital Pharmacy. <i>Actas Urológicas Españolas</i> , 2018 , 42, 375-380	0.7	
33	Review of evidence on handling hazardous drugs and Products in Urology Services; consensus document between the Spanish Urology Association and the Spanish Society of Health-System Pharmacists. <i>Farmacia Hospitalaria</i> , 2018 , 42, 212-215	0.9	
32	Benefit of on nephrectomy for treating metastatic renal cell carcinoma. <i>Actas Urológicas Españolas</i> , 2017 , 41, 338-342	0.7	
31	Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study - GESCAP group. <i>Actas Urológicas Españolas</i> , 2017 , 41, 359-367	0.7	11
30	Metalloproteinase 11, potential marker and molecular target in advanced and castration-resistant prostate cancer. Culture study of peritumoral fibroblasts. <i>Actas Urológicas Españolas</i> , 2017 , 41, 376-382	0.7	1
29	Transcutaneous stimulation of the posterior tibial nerve for treating refractory urge incontinence of idiopathic and neurogenic origin. <i>Actas Urológicas Españolas</i> , 2017 , 41, 465-470	0.7	7
28	Treatment options and predictive factors for recurrence and cancer-specific mortality in bladder cancer after renal transplantation: A multi-institutional analysis. <i>Actas Urológicas Españolas</i> , 2017 , 41, 639-645	0.7	8
27	Stromal factors involved in human prostate cancer development, progression and castration resistance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 351-359	4.9	30
26	Treatment trends for clinically localised prostate cancer. National population analysis: GESCAP group. <i>Actas Urológicas Españolas</i> , 2016 , 40, 209-16	0.7	14

25	GnRH antagonist administration to postpone a weekend intrauterine insemination: a large cohort study from a public center. <i>Reproductive Biology and Endocrinology</i> , 2016 , 14, 53	5	1
24	Maintenance Therapy with 3-monthly Bacillus Calmette-Guërin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. <i>European Urology</i> , 2015 , 68, 256-62	10.2	42
23	Sequential combination of mitomycin C plus bacillus Calmette-Guërin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. <i>European Urology</i> , 2015 , 67, 508-16	10.2	41
22	Molecular classification of non-muscle-invasive bladder cancer (pTa low-grade, pT1 low-grade, and pT1 high-grade subgroups) using methylation of tumor-suppressor genes. <i>Journal of Molecular Diagnostics</i> , 2014 , 16, 564-572	5.1	20
21	Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma. <i>Urologia Internationalis</i> , 2014 , 92, 169-73	1.9	12
20	Editorial Comment to External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guërin. <i>International Journal of Urology</i> , 2014 , 21, 1227-8	2.3	
19	Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guërin response in patients with high-grade non-muscle-invasive bladder carcinoma. <i>European Urology</i> , 2013 , 63, 364-70	10.2	20
18	Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expertS panel. Spanish Association of Urology. <i>Actas Urológicas Españolas</i> , 2013 , 37, 387-94	0.7	3
17	A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness. <i>PLoS ONE</i> , 2013 , 8, e53328	3.7	20
16	Diagnostic value of anti-deamidated gliadin peptide IgG antibodies for celiac disease in children and IgA-deficient patients. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012 , 55, 50-5	2.8	28
15	Peripheral neuropathy: an underdiagnosed cause of erectile dysfunction. <i>BJU International</i> , 2011 , 108, 1855-9	5.6	14
14	The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guërin: external validation of the EORTC risk tables. <i>European Urology</i> , 2011 , 60, 423-30	10.2	121
13	Relationship between metalloprotease expression in tumour and stromal cells and aggressive behaviour in prostate carcinoma: Simultaneous high-throughput study of multiple metalloproteases and their inhibitors using tissue array analysis of radical prostatectomy samples. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011 , 45, 171-6		5
12	Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. <i>Journal of Urology</i> , 2010 , 184, 1507-13	2.5	29
11	Sympathetic skin response in patients with erectile dysfunction. <i>BJU International</i> , 2009 , 104, 1709-12	5.6	14
10	Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. <i>Journal of Urology</i> , 2009 , 182, 2195-203	2.5	337
9	Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guërin: multivariate analysis of data from four randomized CUETO trials. <i>European Urology</i> , 2008 , 53, 992-1001	10.2	188
8	Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. <i>International Journal of Clinical Practice</i> , 2008 , 62, 1076-86	2.9	102

7	Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. <i>European Urology</i> , 2007 , 51, 1267-74	10.2	30
6	A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. <i>European Urology</i> , 2007 , 52, 1398-406	10.2	134
5	Significance of collagenase 3 (matrix metalloproteinase 13) in invasive bladder cancer: correlation with pathological parameters. <i>Urologia Internationalis</i> , 2007 , 78, 140-4	1.9	7
4	Determination of a New Cut-Off Value for the Urinary BTAtak to Optimize the Detection of Recurrences in the Follow-Up of Patients with Superficial Bladder Carcinoma. <i>Current Urology</i> , 2007 , 1, 42-47	1.7	
3	A new form of presentation of renal actinomycosis: renal tumor with retroperitoneal bleeding. <i>Archivos Espanoles De Urologia</i> , 2006 , 59, 756-9	0.4	3
2	Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. <i>Journal of Urology</i> , 2005 , 174, 1242-7	2.5	140
1	Telomere length on bladder washing samples from patients with bladder cancer correlates with tumor characteristics flow cytometry method for quantitative fluorescence in situ hybridization (flow-FISH technique). <i>European Urology</i> , 2005 , 48, 432-7	10.2	2